ArticleInternational journal of mental health and addiction2025
Management of Amphetamine and Methamphetamine Use Disorders: A Systematic Review and Network Meta-analysis of Randomized Trials.
Article in International journal of mental health and addiction, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of cognitive behavioral therapy for stimulant use disorders: a systematic review and meta-analysis.Frontiers in psychiatry · 2025Pooled it
- Care Navigation for Methamphetamine Use Disorder: A Randomized Clinical Trial.JAMA network open · 2026Trial
- A Novel Care Navigation Intervention for Patients with Methamphetamine Use Disorder.Community mental health journal · 2026Trial
- Illicit opioids, methamphetamine/amphetamine, and cocaine use are associated with loss of housing and delay with becoming rehoused across seven diverse cohorts with and without HIV in the United States and Canada.Drug and alcohol dependence reports · 2026Article
- Influence of Translocator Protein (Life (Basel, Switzerland) · 2026Article
- Recruitment feasibility for deep brain stimulation compared to transcranial magnetic stimulation treatment trials for methamphetamine use disorder.Addictive behaviors reports · 2026Article
- Differences in Methamphetamine Use, Self-Reported Impact, and HIV-Related Outcomes by Gender and Sexual Orientation in a Multisite U.S. Cohort of People with HIV in Care.AIDS and behavior · 2026Article
- "I've Never Seen It as a Real Problem": Experiences of Access to Care for People Who Use Methamphetamine.Substance abuse and rehabilitation · 2026Article
- From Pellets to Prizes: Preclinical and Clinical Perspectives on Contingency Management for the Treatment of Substance Use Disorder.Substance abuse and rehabilitation · 2026Review
- Methamphetamine use and associated factors among people who inject drugs in Iran 2020.Substance abuse treatment, prevention, and policy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current evidence regarding effective management of methamphetamine and amphetamine (MA/A) use disorders is inconclusive. Therefore, we assessed the comparative benefits and tolerability of pharmacological, psychosocial, and harm reduction interventions for management of MA/A use disorders. We searched six electronic databases for randomized controlled trials of any pharmacological, psychosocial, or harm reduction interventions in adults with MA/A use disorders. We performed a random-effects frequentist network meta-analysis and used the GRADE approach to assess the certainty of evidence. We included 72 randomized trials (6836 participants). Low certainty evidence suggests quetiapine may extend abstinence compared to placebo [risk ratio (RR) 3.17 (95% confidence intervals (CI), 1.24 to 8.07)] and weekly average proportion of patients with negative urine samples [mean difference (MD) 32.17 (95% CI, 14.08 to 50.26)]. Low certainty evidence also suggested that riluzole may be associated with a higher weekly average proportion of patients with negative urine samples [MD 24.10 (95% CI, 5.54 to 42.66)]. Very low certainty evidence suggests methylphenidate alone [compared to placebo MD 10.24 (95% CI, 3.49 to 16.99)] or in combination with matrix model [MD 23.55 (95% CI, 7.64 to 39.46)] may be associated with an increased weekly average proportion of patients with negative urine samples. Compared to placebo, contingency management alone [MD 21.20 (95% CI, 11.39 to 31.00), very low certainty] or in combination with cognitive behavioural therapy [MD 34.85 (95% CI, 19.63 to 50.08), very low certainty] may be associated with longer duration of abstinence. Compared to placebo, venlafaxine [RR 0.27 (95% CI 0.08 to 0.90), low certainty] and citicoline [RR 0.69 (95% CI 0.49 to 0.99), lowcertainty] may be among the most tolerable interventions. Very few interventions may be associated with slight improvement in certain outcomes, but no intervention showed moderate- to high-certainty evidence for important changes across any patient-important outcomes. Supplementary Information: The online version contains supplementary material available at 10.1007/s11469-024-01379-w.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.